Chicago, Sept. 18, 2018 – Prescient Medicine Holdings, LLC and Metabiomics Corp., have announced a joint venture to develop an innovative microbiome diagnostics platform for detecting precancerous colon polyps and diagnosing other types of gastrointestinal diseases including Crohn’s, colitis (IBD), and irritable bowel syndrome (IBS). The partnership provides the expertise and resources to complete commercialization of Metabiomics’ pipeline of innovative molecular testing solutions. Current plans call for the tests to be available in 2020.
In a Drug Safety Update issued by the UK government on July 12, 2018, Dr. Dave Cardamone’s article titled “Eltrombopag and Serum of a Different Hue” is referenced as the lead publication that describes potential negative interference from eltrombopag on bilirubin testing and positive interference on creatinine test values.
Our Founder & CEO, Dr. Keri Donaldson, sat down with Yahoo Finance's Alexis Christoforous to discuss how to tackle the opioid crisis through solutions that help prevent addiction from occurring.
You can view the interview here: https://finance.yahoo.com/video/doctor-says-test-could-decrease-161955356.html
“I was honored yesterday to be at the White House Opioid Summit on behalf of Prescient Medicine to discuss greater action in the fight against the rising tide of opioid addiction. Data has shown that there is a strong genetic component to opioid addiction, and with the right tools, an individual’s risk of opioid dependency can be predicted. We strongly believe that arming patients and physicians with predictive insight is one of the best solutions to preventing addiction and providing the information needed to make informed decisions before prescribing or taking an opioid.”
Pennsylvania Governor Tom Wolf took an important step today by designating the opioid crisis as a disaster emergency. The announcement marks Pennsylvania as the eighth state to take this type of action and allows government officials, first responders and others greater ability to implement tactics to address the growing epidemic of opioid addiction.
Sponsorship of “Healthcare of Tomorrow” Leadership Forum Helps Drive Conversation Around Solutions
HUMMELSTOWN, PA/November 1, 2017 – Prescient Medicine, a Pennsylvania-based predictive health intelligence company, will sponsor the 5th Annual U.S. News & World Report Healthcare of Tomorrow leadership forum, taking place in Washington, DC on November 1-3, 2017. Founder and CEO, Keri Donaldson, MD, will participate as part of the "Taking Action to Address the Opioid Crisis” panel discussion on Friday, November 3rd at 8:45 a.m. E.T.
Deal Expands Company’s Genetic Testing Capabilities, Managed Care Access
HUMMELSTOWN, PA/October 2, 2017 – Prescient Medicine, a Pennsylvania-based predictive health intelligence company, today announced its acquisition of PGxL Laboratories, a leading reference lab for pharmacogenetics testing. The acquisition will expand Prescient’s laboratory capabilities, and allows the company to grow its relationship with local, regional, and national health insurers, potentially offering patients better access to their suite of pharmacogenomic tools.
Novel Genetic Test Developed by Prescient Medicine Offers Validated Tool to Aid in Combating the Opioid Epidemic
Data Published in Current Issue of Annals of Clinical & Laboratory Science
Prescient Medicine Hosting Opioid Summit in Philadelphia June 20
“SOS: Solving the Opioid Crisis through a Cross-Functional Partnership” will help addiction professionals and others find new ways to address local opioid epidemic
HUMMELSTOWN, Pa., May 24, 2017 -- Prescient Medicine, a leader in Precision Medicine and pharmacogenetics, is pleased to host its first-ever 2017 Opioid Summit, “SOS: SOLVING THE OPIOID CRISIS Through a Cross-Functional Partnership,” June 20 in Philadelphia, Pa. at the Union League Club, 9 a.m. – 3:30 p.m.
Prescient Medicine Presenting Two Posters at Penn State Addiction Symposium April 4
HUMMELSTOWN, Pa., Mar. 31, 2017 -- Prescient Medicine, a leader in Precision Medicine laboratory research and technologies, announced today that it will present two posters at the 3rd Annual Penn State Addiction Symposium April 4, 8 a.m. – 5 p.m., Junker Auditorium, Penn State College of Medicine in Hershey, Pa.